安科生物：2025年上半年公司注射用曲妥珠单抗“安赛汀”销售收入同比增长298%

Core Viewpoint - Anke Bio (300009) reported a significant increase in sales revenue for its injectable trastuzumab "Ansaiting," projecting a year-on-year growth of 298% in the first half of 2025 [1] Group 1 - The company anticipates a substantial rise in sales revenue for its product, indicating strong market demand and potential growth opportunities [1]